However, of the CpGs present on the EPIC platform and located in the proposed super-enhancer region, none were significantly correlated with PD-L1 or PD-L2 FPKM levels in our cell lines or discovery tumor cohort. Here, PDCD1LG2 is linked to neoplasm.